JP2020515259A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515259A5 JP2020515259A5 JP2019553214A JP2019553214A JP2020515259A5 JP 2020515259 A5 JP2020515259 A5 JP 2020515259A5 JP 2019553214 A JP2019553214 A JP 2019553214A JP 2019553214 A JP2019553214 A JP 2019553214A JP 2020515259 A5 JP2020515259 A5 JP 2020515259A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- acid sequence
- seq
- nucleic acid
- rdd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 15
- 150000007523 nucleic acids Chemical group 0.000 claims 15
- 230000011664 signaling Effects 0.000 claims 13
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 11
- 230000000368 destabilizing effect Effects 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 230000001086 cytosolic effect Effects 0.000 claims 9
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 8
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 8
- 108020001756 ligand binding domains Proteins 0.000 claims 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 108010022394 Threonine synthase Proteins 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000004419 dihydrofolate reductase Human genes 0.000 claims 4
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 claims 3
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- FFILOTSTFMXQJC-QCFYAKGBSA-N (2r,4r,5s,6s)-2-[3-[(2s,3s,4r,6s)-6-[(2s,3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(e)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hy Chemical compound O[C@@H]1[C@@H](O)[C@H](OCC(NC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 FFILOTSTFMXQJC-QCFYAKGBSA-N 0.000 claims 2
- 101000908713 Homo sapiens Dihydrofolate reductase Proteins 0.000 claims 2
- 101100446641 Homo sapiens FKBP1A gene Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 102000055209 human FKBP1A Human genes 0.000 claims 2
- 230000031146 intracellular signal transduction Effects 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 claims 1
- 201000011633 childhood acute lymphocytic leukemia Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 238000011577 humanized mouse model Methods 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 229940022919 unituxin Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022193805A JP7674328B2 (ja) | 2017-03-31 | 2022-12-02 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
| JP2024200383A JP2025026930A (ja) | 2017-03-31 | 2024-11-18 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762479930P | 2017-03-31 | 2017-03-31 | |
| US62/479,930 | 2017-03-31 | ||
| PCT/US2018/025459 WO2018183888A2 (en) | 2017-03-31 | 2018-03-30 | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022193805A Division JP7674328B2 (ja) | 2017-03-31 | 2022-12-02 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020515259A JP2020515259A (ja) | 2020-05-28 |
| JP2020515259A5 true JP2020515259A5 (enExample) | 2021-04-08 |
| JP7249287B2 JP7249287B2 (ja) | 2023-03-30 |
Family
ID=63677091
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553214A Active JP7249287B2 (ja) | 2017-03-31 | 2018-03-30 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
| JP2019553220A Active JP7278961B2 (ja) | 2017-03-31 | 2018-03-30 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| JP2022193805A Active JP7674328B2 (ja) | 2017-03-31 | 2022-12-02 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
| JP2023011257A Pending JP2023055805A (ja) | 2017-03-31 | 2023-01-27 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| JP2024123405A Pending JP2024153812A (ja) | 2017-03-31 | 2024-07-30 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| JP2024200383A Pending JP2025026930A (ja) | 2017-03-31 | 2024-11-18 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553220A Active JP7278961B2 (ja) | 2017-03-31 | 2018-03-30 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| JP2022193805A Active JP7674328B2 (ja) | 2017-03-31 | 2022-12-02 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
| JP2023011257A Pending JP2023055805A (ja) | 2017-03-31 | 2023-01-27 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| JP2024123405A Pending JP2024153812A (ja) | 2017-03-31 | 2024-07-30 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| JP2024200383A Pending JP2025026930A (ja) | 2017-03-31 | 2024-11-18 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11938153B2 (enExample) |
| EP (2) | EP3600323A4 (enExample) |
| JP (6) | JP7249287B2 (enExample) |
| CN (3) | CN110603044B (enExample) |
| AU (3) | AU2018243664B2 (enExample) |
| CA (2) | CA3057372A1 (enExample) |
| WO (2) | WO2018183888A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021505604A (ja) * | 2017-12-07 | 2021-02-18 | ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク | ダサチニブ及び他のチロシンキナーゼ阻害剤を用いる遺伝子改変されたキメラ抗原受容体ｔ細胞の機能の制御及び調節 |
| US20210393628A1 (en) * | 2018-10-30 | 2021-12-23 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating t cell exhaustion |
| MX2021005366A (es) | 2018-11-08 | 2021-09-10 | Juno Therapeutics Inc | Metodos y combinaciones para el tratamiento y modulacion de celulas t. |
| EP3931216A4 (en) * | 2019-03-01 | 2023-04-19 | National University of Singapore | MANIPULATED IMMUNE CELLS |
| CN110157680A (zh) * | 2019-05-08 | 2019-08-23 | 浙江大学 | 提高嵌合抗原受体t细胞疗效和作用持久性的细胞培养方法 |
| JP7505784B2 (ja) * | 2019-08-01 | 2024-06-25 | 国立大学法人三重大学 | Ｇｄ２結合性分子 |
| CN115768879A (zh) | 2020-04-28 | 2023-03-07 | 莱尔免疫制药公司 | 用于培养细胞的方法 |
| AU2021292932A1 (en) * | 2020-06-19 | 2023-01-05 | Chugai Seiyaku Kabushiki Kaisha | Anti-T cell antigen-binding molecule for use in combination with angiogenesis inhibitor |
| CN116322691A (zh) * | 2020-09-24 | 2023-06-23 | 豪夫迈·罗氏有限公司 | T细胞双特异性抗体相关不良反应的预防或减轻 |
| WO2022094314A1 (en) * | 2020-10-30 | 2022-05-05 | The University Of North Carolina At Chapel Hill | Dual targeting chimeric antigen receptors |
| WO2022210487A1 (ja) * | 2021-03-29 | 2022-10-06 | タカラバイオ株式会社 | 抗原に特異的な受容体を発現する免疫細胞の製造方法 |
| EP4071248A1 (en) | 2021-04-07 | 2022-10-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Means and methods for enhancing receptor-targeted gene transfer |
| EP4334443A1 (en) * | 2021-05-07 | 2024-03-13 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Method for constitutive malt1 protease activation |
| CN113533729B (zh) * | 2021-06-15 | 2024-09-06 | 北京大学人民医院 | 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用 |
| EP4370541A1 (en) | 2021-07-14 | 2024-05-22 | 2seventy bio, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
| CN115677861A (zh) * | 2021-07-29 | 2023-02-03 | 上海科技大学 | 一种泛素偶联修饰的嵌合抗原受体及免疫细胞 |
| WO2023077026A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing ror1-binding protein |
| CA3234826A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing c-jun |
| CN119546327A (zh) | 2022-04-08 | 2025-02-28 | 再生元制药公司 | 多部分受体和信号传导复合物 |
| KR20250036972A (ko) * | 2022-06-13 | 2025-03-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 개선된 글리칸 의존성 키메라 항원 수용체 세포 |
| GB202218144D0 (en) * | 2022-12-02 | 2023-01-18 | Univ Oxford Innovation Ltd | Product |
| CN116121196B (zh) * | 2022-12-23 | 2025-07-22 | 广州安捷生物医学技术有限公司 | 一种调控car-t细胞的方法与应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057294A (en) | 1995-01-16 | 2000-05-02 | Northern Sydney Area Health Service Of Pacific Highway | Peptide |
| US20050070478A1 (en) | 1996-06-11 | 2005-03-31 | Northern Sydney Area Health Services | T cell antigen receptor peptides |
| US20050113564A1 (en) | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| GB0523954D0 (en) | 2005-11-24 | 2006-01-04 | Ucb Celltech | Bioassays |
| US9334330B2 (en) | 2006-10-10 | 2016-05-10 | Universite De Nantes | Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers |
| US8173792B2 (en) * | 2007-02-09 | 2012-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells using synthetic small molecules |
| EP2664916B1 (en) | 2007-04-02 | 2017-02-08 | Acoustic Cytometry Systems, Inc. | Method for manipulating a fluid medium within a flow cell using acoustic focusing |
| US9493740B2 (en) | 2010-09-08 | 2016-11-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered GD2-specific T cells |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CN107188969B (zh) | 2011-04-08 | 2021-08-27 | 美国卫生和人力服务部 | 抗-表皮生长因子受体变体iii嵌合抗原受体及其用于治疗癌症的用途 |
| MX360823B (es) | 2011-05-24 | 2018-11-16 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Vacunas individualizadas para el cancer. |
| WO2013059593A1 (en) | 2011-10-20 | 2013-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
| EP2785884B1 (en) * | 2011-12-02 | 2020-06-24 | Stillwater Mining Company | Platinum group metal recovery |
| WO2013154760A1 (en) | 2012-04-11 | 2013-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| LT2956175T (lt) | 2013-02-15 | 2017-12-11 | The Regents Of The University Of California | Chimerinis antigeno receptorius ir jo panaudojimo būdai |
| SG11201505896YA (en) | 2013-02-20 | 2015-09-29 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| US9446105B2 (en) | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor β |
| US9790282B2 (en) | 2013-03-25 | 2017-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD276 polypeptides, proteins, and chimeric antigen receptors |
| KR102238226B1 (ko) | 2013-05-14 | 2021-04-09 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용 |
| US9636340B2 (en) * | 2013-11-12 | 2017-05-02 | Ayyappan K. Rajasekaran | Kinase inhibitors |
| GB201403972D0 (en) * | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| WO2015179801A1 (en) * | 2014-05-23 | 2015-11-26 | University Of Florida Research Foundation, Inc. | Car based immunotherapy |
| WO2016011264A1 (en) * | 2014-07-16 | 2016-01-21 | Genentech, Inc. | Methods of treating cancer using tigit inhibitors and anti-cancer agents |
| BR112017001242A2 (pt) | 2014-07-21 | 2017-12-05 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico a cd33 |
| SG10201900455YA (en) * | 2014-07-24 | 2019-02-27 | Bluebird Bio Inc | Bcma chimeric antigen receptors |
| MY189028A (en) | 2014-08-19 | 2022-01-20 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| WO2016061368A1 (en) | 2014-10-15 | 2016-04-21 | The Children's Hospital Of Philadelphia | Compositions and methods for treating b-lymphoid malignancies |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| WO2016134284A1 (en) * | 2015-02-19 | 2016-08-25 | University Of Florida Research Foundation, Inc. | Chimeric antigen receptors and uses thereof |
| EP3270936A4 (en) | 2015-03-17 | 2018-08-08 | Chimera Bioengineering Inc. | Smart car devices, de car polypeptides, side cars and uses thereof |
| GB201514328D0 (en) | 2015-08-12 | 2015-09-23 | Sigmoid Pharma Ltd | Compositions |
| WO2017127755A1 (en) | 2016-01-20 | 2017-07-27 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| AU2017244108B2 (en) * | 2016-03-29 | 2021-03-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| SI3443096T1 (sl) * | 2016-04-15 | 2023-07-31 | Novartis Ag | Sestavki in postopki za selektivno izražanje himerni antigenskih receptorjev |
| JP7098615B2 (ja) * | 2016-12-05 | 2022-07-11 | フェイト セラピューティクス，インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| JP2021505604A (ja) | 2017-12-07 | 2021-02-18 | ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク | ダサチニブ及び他のチロシンキナーゼ阻害剤を用いる遺伝子改変されたキメラ抗原受容体ｔ細胞の機能の制御及び調節 |
| US20210393628A1 (en) | 2018-10-30 | 2021-12-23 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating t cell exhaustion |
-
2018
- 2018-03-30 JP JP2019553214A patent/JP7249287B2/ja active Active
- 2018-03-30 EP EP18775932.9A patent/EP3600323A4/en active Pending
- 2018-03-30 WO PCT/US2018/025459 patent/WO2018183888A2/en not_active Ceased
- 2018-03-30 CA CA3057372A patent/CA3057372A1/en active Pending
- 2018-03-30 CN CN201880029045.8A patent/CN110603044B/zh active Active
- 2018-03-30 WO PCT/US2018/025394 patent/WO2018183842A1/en not_active Ceased
- 2018-03-30 AU AU2018243664A patent/AU2018243664B2/en active Active
- 2018-03-30 JP JP2019553220A patent/JP7278961B2/ja active Active
- 2018-03-30 AU AU2018243571A patent/AU2018243571B2/en active Active
- 2018-03-30 CN CN202410272411.XA patent/CN118161496A/zh active Pending
- 2018-03-30 US US16/499,760 patent/US11938153B2/en active Active
- 2018-03-30 EP EP18777667.9A patent/EP3600357A4/en active Pending
- 2018-03-30 US US16/499,762 patent/US20200101108A1/en active Pending
- 2018-03-30 CA CA3057505A patent/CA3057505A1/en active Pending
- 2018-03-30 CN CN201880028993.XA patent/CN110582280B/zh active Active
-
2022
- 2022-12-02 JP JP2022193805A patent/JP7674328B2/ja active Active
-
2023
- 2023-01-27 JP JP2023011257A patent/JP2023055805A/ja active Pending
-
2024
- 2024-02-21 US US18/583,096 patent/US20240293461A1/en active Pending
- 2024-06-07 AU AU2024203919A patent/AU2024203919A1/en active Pending
- 2024-07-30 JP JP2024123405A patent/JP2024153812A/ja active Pending
- 2024-11-18 JP JP2024200383A patent/JP2025026930A/ja active Pending